geometrybase
8a0dfd88f0
Request: - Add extracted PDF text generation to the archivist workflow as a standard step. Changes: - Run PDF text extraction automatically for newly archived HKEX PDF sources. - Make the PDF text extractor incremental and manifest-preserving. - Document extracted-text handling in the archivist skill and README. - Mark generated extracted text as no-diff data evidence. - Backfill extracted text for all archived PDF source references. Verification: - Ran git diff --cached --check. - Ran .venv/bin/python -m py_compile scripts/extract_pdf_text.py scripts/archive_hkex_documents.py. - Ran full PDF extraction, then confirmed an incremental rerun skips unchanged files. - Verified 557 PDF source_refs, 557 manifest rows, all status ok, and zero missing text/hash/path issues. Next useful context: - HKEX HTML notices and Yahoo JSON market data remain under data/raw and are not expected in data/extracted_text.
3609 lines
88 KiB
Plaintext
3609 lines
88 KiB
Plaintext
--- page 1 ---
|
||
1
|
||
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange ”)
|
||
and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no responsibility for the contents of this
|
||
announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability
|
||
whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this
|
||
announcement.
|
||
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States
|
||
(including its territories and possessions, any state of the United States and the District of Columbia). This
|
||
announcement does not, and is not intended to, constitute or form a part of any offer or solicitation to purchase or
|
||
subscribe for securities in the United States or in any other jurisdiction. The Offer Shares have not been and will not be
|
||
registered under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act ”) or
|
||
securities law of any state or other jurisdiction of the United States and may not be offered, sold, pledged or otherwise
|
||
transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements
|
||
of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of
|
||
the Offer Shares in the United States. The Offer Shares are being offered and sold solely (1) to qualified institutional
|
||
buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S.
|
||
Securities Act; and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S.
|
||
Securities Act and applicable laws of each jurisdiction where those offers and sales occur.
|
||
This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase
|
||
or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated
|
||
September 11, 2025 (the “Prospectus ”) issued by GenFleet Therapeutics (Shanghai) Inc. (Ҧ (ɪऎ)΅Ϟ
|
||
ʮ̡) (the “Company ”) for detailed information about the Global Offering described below before deciding whether
|
||
or not to invest in the H Shares thereby being offered. The Company has not been and will not be registered under the
|
||
U.S. Investment Company Act of 1940, as amended.
|
||
Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those
|
||
defined in the Prospectus.
|
||
In connection with the Global Offering, CLSA Limited as stabilizing manager (the “Stabilizing Manager ”) (or its
|
||
affiliates or any person acting for it) on behalf of the Underwriters, to the extent permitted by the applicable laws and
|
||
regulatory requirements of Hong Kong or elsewhere, may make purchases, over-allocate or effect transactions in the
|
||
market or otherwise take such stabilizing action(s) with a view to stabilizing or supporting the market price of the H
|
||
Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However,
|
||
there is no obligation on the Stabilizing Manager (or its affiliates or any person acting for it) to conduct any such
|
||
stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilizing
|
||
Manager (or its affiliates or any person acting for it) and in what the Stabilizing Manager reasonably regards as the
|
||
best interest of the Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30
|
||
days after the last day for lodging applications under the Hong Kong Public Offering.
|
||
Potential investors should note that no stabilizing action can be taken to support the price of the H Shares for longer
|
||
than the stabilization period, which will begin on the Listing Date and is expected to expire on Thursday, October
|
||
16, 2025, being the 30th day after the last day for lodging applications under the Hong Kong Public Offering. After
|
||
this date, when no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H
|
||
Shares, could fall.
|
||
The obligations of the Hong Kong Underwriters under the Hong Kong Underwriting Agreement to subscribe for,
|
||
and to procure subscribers for, the Hong Kong Offer Shares, are subject to termination by the Sole Sponsor-Overall
|
||
Coordinator (for itself and on behalf of the Underwriters) if certain events shall occur prior to 8:00 a.m. on the Listing
|
||
Date. Such grounds are set out in the section headed “Underwriting ” in the Prospectus. It is important that you refer to
|
||
that section for further details.
|
||
|
||
|
||
--- page 2 ---
|
||
2
|
||
GenFleet Therapeutics (Shanghai) Inc.
|
||
ʮ̡
|
||
(A joint stock company incorporated in the People ’s Republic of China with limited liability)
|
||
GLOBAL OFFERING
|
||
Number of Offer Shares under the
|
||
Global Offering
|
||
: 89,240,000 H Shares (taking into account
|
||
the full exercise of the Offer Size
|
||
Adjustment Option and subject to the
|
||
Over-allotment Option)
|
||
Number of Hong Kong Offer Shares : 7,760,000 H Shares
|
||
Number of International Offer Shares : 81,480,000 H Shares (taking into account
|
||
the full exercise of the Offer Size
|
||
Adjustment Option and subject to the
|
||
Over-allotment Option)
|
||
Offer Price : HK$20.39 per Offer Share, plus brokerage
|
||
of 1.0%, SFC transaction levy of
|
||
0.0027%, AFRC transaction levy of
|
||
0.00015% and Hong Kong Stock
|
||
Exchange trading fee of 0.00565%
|
||
Nominal value : RMB0.1 per H Share
|
||
Stock code : 2595
|
||
Sole Sponsor, Sole Sponsor-Overall Coordinator, Joint Global Coordinator,
|
||
Joint Bookrunner and Joint Lead Manager
|
||
Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers
|
||
Joint Bookrunners, Joint Lead Managers and/or Joint Global Coordinator
|
||
|
||
|
||
--- page 3 ---
|
||
3
|
||
GENFLEET THERAPEUTICS (SHANGHAI) INC./Ҧ (ɪऎ)ʮ̡
|
||
ANNOUNCEMENT OF ALLOTMENT RESULTS
|
||
Unless otherwise defined herein, capitalized terms used in this announcement shall have the same
|
||
meanings as those defined in the prospectus dated September 11, 2025 (the “Prospectus ”) issued
|
||
by GenFleet Therapeutics (Shanghai) Inc. (Ҧ (ɪऎ)ʮ̡ ) (the “Company ”).
|
||
Warning: In view of high concentration of shareholding in a small number of Shareholders,
|
||
Shareholders and prospective investors should be aware that the price of the H Shares
|
||
could move substantially even with a small number of H Shares traded and should exercise
|
||
extreme caution when dealing in the H Shares.
|
||
SUMMARY
|
||
Company information
|
||
Stock code 2595
|
||
Stock short name GENFLEET-B
|
||
Dealings commencement date September 19, 2025*
|
||
* see note at the end of the announcement
|
||
Price Information
|
||
Fixed Offer Price HK$20.39
|
||
Offer Shares and Share Capital
|
||
Number of Offer Shares 89,240,000 H Shares
|
||
Final Number of Offer Shares in Hong Kong Public Offering 7,760,000 H Shares
|
||
Final Number of Offer Shares in International Offering (taking
|
||
into account the full exercise of the Offer Size Adjustment
|
||
Option and subject to the Over-allotment Option)
|
||
81,480,000 H Shares
|
||
Number of issued shares upon Listing (before any exercise of
|
||
the Over-allotment Option)
|
||
356,980,630 Shares
|
||
The number of Offer Shares above is determined after taking into account the additional shares
|
||
issued under the following Offer Size Adjustment Option.
|
||
|
||
|
||
--- page 4 ---
|
||
4
|
||
Offer Size Adjustment Option (Upsize option)
|
||
Number of additional shares issued under the option 11,640,000 H Shares
|
||
– International Offering 11,640,000 H Shares
|
||
Over-allocation
|
||
No. of Offer Shares over-allocated 13,386,000 H Shares
|
||
– International Offering 13,386,000 H Shares
|
||
Such over-allocation may be covered by exercising the Over-allotment Option or by making
|
||
purchases in the secondary market at prices that do not exceed the Offer Price or a combination
|
||
of these means. In the event the Over-allotment Option is exercised, an announcement will be
|
||
made on the Stock Exchange ’s website.
|
||
Proceeds
|
||
Gross proceeds (Note) HK$1,819.60 million
|
||
Less: Estimated listing expenses payable based on the
|
||
Offer Price
|
||
HK$149.69 million
|
||
Net proceeds HK$1,669.92 million
|
||
Note: Gross proceeds refer to the amount to which the issuer is entitled to receive. For details of the use of
|
||
proceeds, please refer to the Prospectus dated September 11, 2025.
|
||
|
||
|
||
--- page 5 ---
|
||
5
|
||
ALLOTMENT RESULTS DETAILS
|
||
HONG KONG PUBLIC OFFERING
|
||
No. of valid applications 257,876
|
||
No. of successful applications 32,905
|
||
Subscription level 2,662.79
|
||
times
|
||
Claw-back triggered N/A
|
||
No. of Offer Shares initially available under the Hong Kong Public Offering 7,760,000
|
||
H Shares
|
||
No. of Offer Shares reallocated from the International Offering (claw-back) N/A
|
||
Final no. of Offer Shares under the Hong Kong Public Offering 7,760,000
|
||
H Shares
|
||
% of Offer Shares under the Hong Kong Public Offering to the Global
|
||
Offering
|
||
8.7%
|
||
Note: For details of the final allocation of shares to the Hong Kong Public Offering, investors can
|
||
refer to https://www.eipo.com.hk/eIPOAllotment to perform a search by identification number or
|
||
https://www.eipo.com.hk/eIPOAllotment for the full list of allottees.
|
||
INTERNATIONAL OFFERING
|
||
No. of placees 162
|
||
Subscription Level 39.05 times
|
||
No. of Offer Shares initially available under the International Offering 69,840,000
|
||
H Shares
|
||
No. of Offer Shares reallocated to the Hong Kong Public Offering
|
||
(claw-back)
|
||
N/A
|
||
Final no. of Offer Shares under the International Offering
|
||
(taking into account the full exercise of the Offer Size Adjustment Option)
|
||
81,480,000
|
||
H Shares
|
||
% of Offer Shares under the International Offering to the Global Offering 91.3%
|
||
|
||
|
||
--- page 6 ---
|
||
6
|
||
The Directors confirm that, to the best of their knowledge, information and belief, save for a
|
||
consent under paragraph 1C(2) of Appendix F1 to the Listing Rules (the “Placing Guidelines ”)
|
||
granted by the Stock Exchange to permit the Company to allocate certain Offer Shares in the
|
||
International Offering to close associates of existing Shareholders of the Company granted by
|
||
the Stock Exchange, (i) none of the Offer Shares subscribed by the placees and the public have
|
||
been financed directly or indirectly by the Company, any of the Directors, chief executive of the
|
||
Company, Supervisors, controlling Shareholders, substantial Shareholders, existing Shareholders
|
||
of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the
|
||
placees and the public who have purchased the Offer Shares are accustomed to taking instructions
|
||
from the Company, any of the Directors, chief executive of the Company, Supervisors, controlling
|
||
Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its
|
||
subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or
|
||
other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.
|
||
|
||
|
||
--- page 7 ---
|
||
7
|
||
The placees in the International offer include the following:
|
||
Cornerstone Investors
|
||
Investor (1)
|
||
Number of
|
||
Offer Shares
|
||
allocated
|
||
% of Offer
|
||
Shares (2)
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering (2)
|
||
% of total
|
||
issued share
|
||
capital after
|
||
the Global
|
||
Offering (2)
|
||
Existing
|
||
shareholders
|
||
or their close
|
||
associates
|
||
RTW Master Fund, Ltd. 3,054,200 3.42% 0.94% 0.86% No
|
||
RTW Innovation Master
|
||
Fund, Ltd.
|
||
2,444,400 2.74% 0.75% 0.68% No
|
||
RTW Biotech Opportunities
|
||
Operating Ltd.
|
||
236,600 0.27% 0.07% 0.07% No
|
||
TruMed Health Innovation
|
||
Fund LP
|
||
4,397,000 4.93% 1.35% 1.23% No
|
||
TruMed Healthcare
|
||
Master Fund
|
||
382,200 0.43% 0.12% 0.11% No
|
||
OrbiMed Genesis
|
||
Master Fund, L.P.
|
||
1,903,000 2.13% 0.59% 0.53% No
|
||
OrbiMed Partners
|
||
Master Fund Limited
|
||
1,759,600 1.97% 0.54% 0.49% No
|
||
The Biotech Growth Trust PLC 1,116,600 1.25% 0.34% 0.31% No
|
||
UBS Asset Management
|
||
(Singapore) Ltd.
|
||
3,823,400 4.28% 1.18% 1.07% No
|
||
Vivo Opportunity Fund
|
||
Holdings, L.P.
|
||
3,472,800 3.89% 1.07% 0.97% No
|
||
Vivo Opportunity
|
||
Caymen Fund, L.P.
|
||
350,600 0.39% 0.11% 0.10% No
|
||
China Universal Asset
|
||
Management (Hong Kong)
|
||
Company Limited
|
||
3,058,800 3.43% 0.94% 0.86% No
|
||
China Universal Asset
|
||
Management Company
|
||
Limited (ږ
|
||
ʮ̡ )
|
||
764,600 0.86% 0.24% 0.21% No
|
||
Fullgoal Fund Management
|
||
Co., Ltd. (၍ଣ
|
||
ʮ̡ )
|
||
3,058,800 3.43% 0.94% 0.86% No
|
||
Fullgoal Asset Management
|
||
(HK) Limited
|
||
764,600 0.86% 0.24% 0.21% No
|
||
|
||
|
||
--- page 8 ---
|
||
8
|
||
Investor (1)
|
||
Number of
|
||
Offer Shares
|
||
allocated
|
||
% of Offer
|
||
Shares (2)
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering (2)
|
||
% of total
|
||
issued share
|
||
capital after
|
||
the Global
|
||
Offering (2)
|
||
Existing
|
||
shareholders
|
||
or their close
|
||
associates
|
||
CITIC Securities International
|
||
Capital Management Limited
|
||
(in connection with Tibet
|
||
Longrising OTC Swaps)
|
||
3,823,400 4.28% 1.18% 1.07% No
|
||
LBC HK Opportunity Fund 1,533,200 1.72% 0.47% 0.43% Yes(2)
|
||
Lake Bleu Prime
|
||
Healthcare Fund
|
||
1,464,400 1.64% 0.45% 0.41% Yes(2)
|
||
Lake Bleu Innovation Fund 825,800 0.93% 0.25% 0.23% Yes(2)
|
||
Total 38,234,000 42.84% 11.78% 10.71%
|
||
Notes:
|
||
(1) For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors ” in
|
||
the Prospectus.
|
||
(2) Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-
|
||
allotment Option.
|
||
(3) For details of a consent under paragraph 1C(2) of the Placing Guidelines granted by the Stock Exchange to
|
||
permit the Company to allocate certain Offer Shares in the International Offering to close associates of a
|
||
minority existing Shareholder as cornerstone investors, please refer to the section headed “Other Information ” in
|
||
this announcement.
|
||
|
||
|
||
--- page 9 ---
|
||
9
|
||
Allotees with Waivers/Consents Obtained
|
||
Investor
|
||
Number of
|
||
Offer Shares
|
||
allocated
|
||
% of Offer
|
||
Shares (1)
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering (1)
|
||
% of total
|
||
issued share
|
||
capital after
|
||
the Global
|
||
Offering (1) Relationship
|
||
Allotees with consent under paragraph 1C(2) of the Placing Guidelines in relation to subscription for Offer Shares by
|
||
close associates of existing Shareholders (2)
|
||
LBC HK
|
||
Opportunity
|
||
Fund
|
||
1,533,200 1.72% 0.47% 0.43% A close associate
|
||
of an existing
|
||
Shareholder and
|
||
a Cornerstone
|
||
Investor
|
||
Lake Bleu Prime
|
||
Healthcare Fund
|
||
1,464,400 1.64% 0.45% 0.41% A close associate
|
||
of an existing
|
||
Shareholder and
|
||
a Cornerstone
|
||
Investor
|
||
Lake Bleu
|
||
Innovation Fund
|
||
825,800 0.93% 0.25% 0.23% A close associate
|
||
of an existing
|
||
Shareholder and
|
||
a Cornerstone
|
||
Investor
|
||
GF International
|
||
Investment
|
||
Management
|
||
Limited ( “GF
|
||
International ”)
|
||
1,145,000 1.28% 0.35% 0.32% A close associate
|
||
of an existing
|
||
Shareholder,
|
||
a connected client
|
||
of GF Securities
|
||
(Hong Kong)
|
||
Brokerage Limited
|
||
( “GF Securities
|
||
(Hong Kong)
|
||
Brokerage ”) and
|
||
a placee
|
||
Value Partners
|
||
Hong Kong
|
||
Limited ( “Value
|
||
Partners ”)
|
||
8,800 0.01% 0.003% 0.002% A close associate
|
||
of an existing
|
||
Shareholder,
|
||
a connected client
|
||
of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and
|
||
a placee
|
||
|
||
|
||
--- page 10 ---
|
||
10
|
||
Investor
|
||
Number of
|
||
Offer Shares
|
||
allocated
|
||
% of Offer
|
||
Shares (1)
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering (1)
|
||
% of total
|
||
issued share
|
||
capital after
|
||
the Global
|
||
Offering (1) Relationship
|
||
E Fund
|
||
Management
|
||
Co., Ltd. (˙
|
||
၍ଣ
|
||
ʮ̡ )
|
||
( “E Fund
|
||
Management ”)
|
||
1,425,000 1.60% 0.44% 0.40% A close associate
|
||
of an existing
|
||
Shareholder,
|
||
a connected client
|
||
of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and
|
||
a placee
|
||
E Fund
|
||
Management
|
||
(Hong Kong)
|
||
Co., Limited
|
||
(˙༺༟ପ
|
||
၍ଣ(ಥ)
|
||
ʮ̡ )
|
||
( “E Fund HK ”)
|
||
104,000 0.12% 0.03% 0.03% A close associate
|
||
of an existing
|
||
Shareholder,
|
||
a connected client
|
||
of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and
|
||
a placee
|
||
Five Investment
|
||
Limited ( “Five
|
||
Investment ”)
|
||
1,720,200 1.93% 0.53% 0.48% A close associate
|
||
of an existing
|
||
Shareholder and
|
||
a placee
|
||
Apricot BioScience
|
||
Holdings, L.P.
|
||
(“Apricot
|
||
BioScience ”)
|
||
1,911,000 2.14% 0.59% 0.54% A close associate
|
||
of an existing
|
||
Shareholder and a
|
||
placee
|
||
Allotees with consent under paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients (2)
|
||
CITIC Securities
|
||
International
|
||
Capital
|
||
Management
|
||
Limited
|
||
( “CSICM”) (in
|
||
connection with
|
||
Tibet Longrising
|
||
OTC Swaps)
|
||
3,823,400 4.28% 1.18% 1.07% A connected client of
|
||
CLSA Limited
|
||
( “CLSA”)
|
||
and a Cornerstone
|
||
Investor
|
||
GF International 1,145,000 1.28% 0.35% 0.32% A close associate
|
||
of an existing
|
||
Shareholder,
|
||
a connected client
|
||
of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and
|
||
a placee
|
||
|
||
|
||
--- page 11 ---
|
||
11
|
||
Investor
|
||
Number of
|
||
Offer Shares
|
||
allocated
|
||
% of Offer
|
||
Shares (1)
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering (1)
|
||
% of total
|
||
issued share
|
||
capital after
|
||
the Global
|
||
Offering (1) Relationship
|
||
Value Partners 8,800 0.01% 0.003% 0.002% A close associate
|
||
of an existing
|
||
Shareholder,
|
||
a connected client
|
||
of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and
|
||
a placee
|
||
E Fund Hong Kong 104,000 0.12% 0.03% 0.03% A close associate
|
||
of an existing
|
||
Shareholder,
|
||
a connected client
|
||
of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and
|
||
a placee
|
||
E Fund
|
||
Management
|
||
1,425,000 1.60% 0.44% 0.40% A close associate
|
||
of an existing
|
||
Shareholder,
|
||
a connected client
|
||
of GF Securities
|
||
(Hong Kong)
|
||
Brokerage and
|
||
a placee
|
||
CSICM (in
|
||
connection
|
||
with Beijing
|
||
Heyiyingtong
|
||
OTC Swaps (3))
|
||
3,800 0.004% 0.001% 0.001% A connected client
|
||
of CLSA
|
||
and a placee
|
||
CSICM (in
|
||
connection
|
||
with HY Capital
|
||
OTC Swaps (3))
|
||
229,400 0.26% 0.07% 0.06% A connected client
|
||
of CLSA and
|
||
a placee
|
||
|
||
|
||
--- page 12 ---
|
||
12
|
||
Investor
|
||
Number of
|
||
Offer Shares
|
||
allocated
|
||
% of Offer
|
||
Shares (1)
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering (1)
|
||
% of total
|
||
issued share
|
||
capital after
|
||
the Global
|
||
Offering (1) Relationship
|
||
CSICM (in
|
||
connection with
|
||
Shanghai Panjing
|
||
OTC Swaps (3))
|
||
573,400 0.64% 0.18% 0.16% A connected client
|
||
of CLSA and
|
||
a placee
|
||
CSICM (in
|
||
connection with
|
||
Shanghai Juming
|
||
OTC Swaps (3))
|
||
400 0.0004% 0.0001% 0.0001% A connected client
|
||
of CLSA and
|
||
a placee
|
||
CSICM (in
|
||
connection
|
||
with Shenzhen
|
||
Hongchou OTC
|
||
Swaps (3))
|
||
305,600 0.34% 0.09% 0.09% A connected client
|
||
of CLSA and
|
||
a placee
|
||
CSICM (in
|
||
connection
|
||
with Shanghai
|
||
Pinpoint OTC
|
||
Swaps (3))
|
||
400 0.0004% 0.0001% 0.0001% A connected client
|
||
of CLSA and
|
||
a placee
|
||
|
||
|
||
--- page 13 ---
|
||
13
|
||
Investor
|
||
Number of
|
||
Offer Shares
|
||
allocated
|
||
% of Offer
|
||
Shares (1)
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering (1)
|
||
% of total
|
||
issued share
|
||
capital after
|
||
the Global
|
||
Offering (1) Relationship
|
||
CSICM (in
|
||
connection
|
||
with Shenzhen
|
||
Baoheng OTC
|
||
Swaps (3))
|
||
200 0.0002% 0.0001% 0.0001% A connected client
|
||
of CLSA and
|
||
a placee
|
||
CITIC Securities
|
||
Asset
|
||
Management
|
||
Company
|
||
Limited
|
||
( “CITIC Asset
|
||
Management ”)
|
||
8,800 0.01% 0.003% 0.002% A connected client
|
||
of CLSA and
|
||
a placee
|
||
China Asset
|
||
Management
|
||
(Hong Kong)
|
||
Limited ( “China
|
||
AMC HK ”)
|
||
19,000 0.02% 0.01% 0.01% A connected client
|
||
of CLSA and
|
||
a placee
|
||
Notes:
|
||
(1) Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the Over-allotment Option.
|
||
(2) For details of (i) the consent under paragraph 1C(2) of the Placing Guidelines granted by the Stock Exchange to permit the Company
|
||
to allocate certain Offer Shares in the International Offering to close associates of existing Shareholders, and (ii) the consent under
|
||
paragraph 1C(1) of the Placing Guidelines in relation to allocations to connected clients, please refer to the section headed “Waivers and
|
||
Exemption ” in the Prospectus and the section headed “Other Information ” in this announcement.
|
||
(3) As defined in the section headed “Other Information - Placing to connected clients with prior consent under paragraph 1C(1) of the
|
||
Placing Guidelines ” in this announcement.
|
||
|
||
|
||
--- page 14 ---
|
||
14
|
||
LOCK-UP UNDERTAKINGS
|
||
Pre-IPO Investors (as defined in the “History, Development and Corporate Structure ” section
|
||
of the Prospectus)
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Ourea Biotech HK
|
||
Limited
|
||
22,418,890 22,418,890 6.91% 6.28% September 18, 2026
|
||
Long Star Growth
|
||
Group Limited
|
||
(ණྠ
|
||
ʮ̡ )
|
||
15,091,150 15,091,150 4.65% 4.23% September 18, 2026
|
||
Beijing Huagai
|
||
Xincheng
|
||
Yuanhang
|
||
Medical Industry
|
||
Investment
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(༐
|
||
Ⴣঘᔼᐕପุ
|
||
ҳ༟ΥྫΆุ
|
||
(Υྫ ))
|
||
7,467,550 7,467,550 2.30% 2.09% September 18, 2026
|
||
Capital Health
|
||
Industry
|
||
(Beijing)
|
||
Fund (Limited
|
||
Partnership)
|
||
(ேɽੰପุ
|
||
( ̏ԯ)ږ
|
||
( Υྫ ))
|
||
7,467,550 7,467,550 2.30% 2.09% September 18, 2026
|
||
Hongyong Bingde
|
||
(Hong Kong)
|
||
Limited ( ᒿ͑
|
||
ᅃ(ಥ)
|
||
ʮ̡ )
|
||
13,171,820 0 0.00% 3.69% September 18, 2026
|
||
|
||
|
||
--- page 15 ---
|
||
15
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Shenzhen Hongtu
|
||
Healthcare
|
||
Industry Equity
|
||
Investment Fund
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ɺᔼᐕ
|
||
ᛆ
|
||
Υྫ
|
||
Άุ(Υྫ ))
|
||
8,960,120 8,960,120 2.76% 2.51% September 18, 2026
|
||
Shenzhen Capital
|
||
Group Co., Ltd.
|
||
( ଉέ̹௴อҳ༟
|
||
ʮ̡ )
|
||
1,493,350 1,493,350 0.46% 0.42% September 18, 2026
|
||
Guangzhou
|
||
Chenhui Venture
|
||
Capital Fund
|
||
Partnership
|
||
Enterprise
|
||
(Limited
|
||
Partnership)
|
||
( ᄿψԕሾ௴ุ
|
||
Υྫ
|
||
Άุ(Υྫ ))
|
||
5,643,250 5,643,250 1.74% 1.58% September 18, 2026
|
||
Guangzhou Chentu
|
||
No. 14 Venture
|
||
Capital Fund
|
||
Partnership
|
||
Enterprise
|
||
(Limited
|
||
Partnership)
|
||
( ᄿψԕ
|
||
ɤ̬௴ุҳ༟
|
||
ΥྫΆุ
|
||
(Υྫ ))
|
||
2,800,170 2,800,170 0.86% 0.78% September 18, 2026
|
||
|
||
|
||
--- page 16 ---
|
||
16
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Guangzhou Chentu
|
||
No. 15 Venture
|
||
Capital Fund
|
||
Partnership
|
||
Enterprise
|
||
(Limited
|
||
Partnership)
|
||
( ᄿψԕ
|
||
ɤʞ௴ุҳ༟
|
||
ΥྫΆุ
|
||
(Υྫ ))
|
||
1,400,210 1,400,210 0.43% 0.39% September 18, 2026
|
||
Sinopharm
|
||
(Shanghai)
|
||
Biological Equity
|
||
Investment Fund
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
( ᖹʕ͛ (ɪऎ)
|
||
ᛆҳ༟
|
||
ΥྫΆุ
|
||
(Υྫ ))
|
||
9,476,150 4,738,075 1.46% 2.65% September 18, 2026
|
||
Suzhou Apricot
|
||
Xingyong
|
||
Emerging
|
||
Medical Industry
|
||
Investment Fund
|
||
Management
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
( ᘽψҾዣጳಪ
|
||
อጳᔼᐕପุ
|
||
၍ଣ
|
||
ΥྫΆุ
|
||
(Υྫ ))
|
||
7,761,990 7,761,990 2.39% 2.17% September 18, 2026
|
||
|
||
|
||
--- page 17 ---
|
||
17
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Ningbo Huiqiao
|
||
Hongjia
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ි̾͠
|
||
௴ุҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
8,871,870 8,871,870 2.73% 2.49% September 18, 2026
|
||
Beta Achieve
|
||
Limited
|
||
4,069,190 4,069,190 1.25% 1.14% September 18, 2026
|
||
Suzhou Jichuang
|
||
Xinyuan
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(๕
|
||
௴ุҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
2,905,570 2,905,570 0.90% 0.81% September 18, 2026
|
||
Chongqing
|
||
Jichuang
|
||
Fengyuan
|
||
Private Equity
|
||
Investment Fund
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ᅅ௴㋘๕
|
||
ᛆҳ༟
|
||
ΥྫΆุ
|
||
(Υྫ ))
|
||
1,163,620 1,163,620 0.36% 0.33% September 18, 2026
|
||
|
||
|
||
--- page 18 ---
|
||
18
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Shanghai Panlong
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
( ɪऎᇂᗬ௴ุ
|
||
ҳ༟ΥྫΆุ
|
||
(Υྫ ))
|
||
4,480,060 4,480,060 1.38% 1.25% September 18, 2026
|
||
Hangzhou
|
||
Panlin Xukang
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ψᇂᎌϛੰ
|
||
௴ุҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
1,866,950 1,866,950 0.58% 0.52% September 18, 2026
|
||
Qingdao Panlin
|
||
Hongyu
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ᇂᎌᒿ༃
|
||
௴ุҳ༟Άุ
|
||
(Υྫ ))
|
||
1,743,940 1,743,940 0.54% 0.49% September 18, 2026
|
||
Shaoxing Haibang
|
||
Caizhi Venture
|
||
Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
( ୗጳऎԞʑ౽
|
||
௴ุҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
3,487,880 3,487,880 1.07% 0.98% September 18, 2026
|
||
|
||
|
||
--- page 19 ---
|
||
19
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Shaoxing Haibang
|
||
Talent Venture
|
||
Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
( ୗጳऎԞɛʑ
|
||
௴ุҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
3,221,290 3,221,290 0.99% 0.90% September 18, 2026
|
||
GF Qianhe
|
||
Investment Co.,
|
||
Ltd. ( ᄿ೯৻ձ
|
||
ʮ̡ )
|
||
4,764,960 4,764,960 1.47% 1.33% September 18, 2026
|
||
Zhuhai Huajin
|
||
Lingjian Equity
|
||
Investment Fund
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ჯ
|
||
ږ
|
||
ΥྫΆุ
|
||
(Υྫ ))
|
||
4,702,710 2,351,360 0.72% 1.32% September 18, 2026
|
||
Hangzhou
|
||
Taikun Equity
|
||
Investment Fund
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ᛆ
|
||
Υྫ
|
||
Άุ(Υྫ ))
|
||
4,702,710 4,702,710 1.45% 1.32% September 18, 2026
|
||
|
||
|
||
--- page 20 ---
|
||
20
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Suzhou Suxin
|
||
Guokang
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(
|
||
ੰ௴ุҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
1,866,950 1,866,950 0.58% 0.52% September 18, 2026
|
||
Suzhou Suxin
|
||
Junnuo
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ёፕ
|
||
௴ุҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
1,866,950 1,866,950 0.58% 0.52% September 18, 2026
|
||
Suzhou Suxin
|
||
Qikang
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(઼ੰ
|
||
௴ุҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
933,470 933,470 0.29% 0.26% September 18, 2026
|
||
Hangzhou Jingxin
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ψᗝː௴ุ
|
||
ҳ༟ΥྫΆุ
|
||
(Υྫ ))
|
||
4,480,060 4,480,060 1.38% 1.25% September 18, 2026
|
||
|
||
|
||
--- page 21 ---
|
||
21
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
CSPC NBP
|
||
Pharmaceutical
|
||
Co., Ltd. ( ͩᖹ
|
||
̀౷ᖹุ
|
||
ʮ̡ ))
|
||
4,411,760 0 0.00% 1.24% September 18, 2026
|
||
Jiaxing Runji
|
||
Equity
|
||
Investment
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ᛆ
|
||
ҳ༟ΥྫΆุ
|
||
(Υྫ ))
|
||
2,325,250 2,325,250 0.72% 0.65% September 18, 2026
|
||
Qingdao Shanjin
|
||
Anjia Equity
|
||
Investment
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(τྗ
|
||
ᛆҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
1,866,950 1,866,950 0.58% 0.52% September 18, 2026
|
||
Shijiazhuang
|
||
High-Tech
|
||
Zone Pu ’en
|
||
Guoxin Equity
|
||
Investment
|
||
Centre (Limited
|
||
Partnership)
|
||
(৷อਜ
|
||
ᛆ
|
||
ҳ༟ʕː
|
||
(Υྫ ))
|
||
3,956,070 0 0.00% 1.11% September 18, 2026
|
||
|
||
|
||
--- page 22 ---
|
||
22
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Shanghai Taiyi
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
( ɪऎइӥ௴ุ
|
||
ҳ༟ΥྫΆุ
|
||
(Υྫ ))
|
||
3,399,190 3,399,190 1.05% 0.95% September 18, 2026
|
||
Shanghai
|
||
Yuhan Equity
|
||
Investment Fund
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ᛆ
|
||
Υྫ
|
||
Άุ(Υྫ ))
|
||
3,317,020 3,317,020 1.02% 0.93% September 18, 2026
|
||
Huimei Jiankang
|
||
Haihe (Tianjin)
|
||
Private Equity
|
||
L.P. ( ӊੰ
|
||
ئ(ݵ)ᛆ
|
||
Υྫ
|
||
Άุ(Υྫ ))
|
||
3,072,130 3,072,130 0.95% 0.86% September 18, 2026
|
||
LBC Sunshine
|
||
Healthcare Fund
|
||
II L.P.
|
||
2,940,240 2,940,240 0.91% 0.82% September 18, 2026
|
||
Xiamen Dyee
|
||
Evergreen
|
||
Venture Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ڡڗ
|
||
௴ุҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
2,800,170 2,800,170 0.86% 0.78% September 18, 2026
|
||
|
||
|
||
--- page 23 ---
|
||
23
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Suqian Lingdao
|
||
Shengming
|
||
Changqing
|
||
Equity
|
||
Investment
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
( ቋჯ༸͛ն
|
||
ᛆҳ༟
|
||
ΥྫΆุ
|
||
(Υྫ ))
|
||
1,926,610 1,926,610 0.59% 0.54% September 18, 2026
|
||
BOCOM Sci-Tech
|
||
Innovation
|
||
Equity
|
||
Investment
|
||
Fund (Shanghai)
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ᛆ
|
||
ږ( ɪऎ)
|
||
ΥྫΆุ
|
||
(Υྫ ))
|
||
1,890,480 0 0.00% 0.53% September 18, 2026
|
||
Suzhou Jingtian
|
||
Medical
|
||
Investment
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
( ᘽψ౻˂ᔼᐕ
|
||
ҳ༟ΥྫΆุ
|
||
(Υྫ ))
|
||
1,866,950 933,475 0.29% 0.52% September 18, 2026
|
||
BV Fund II L.P. 1,866,950 1,866,950 0.58% 0.52% September 18, 2026
|
||
|
||
|
||
--- page 24 ---
|
||
24
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Zhuzhou Wenzhou
|
||
Junzhe Venture
|
||
Capital
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(̹˖մё䂮
|
||
௴ุҳ༟Υྫ
|
||
Άุ(Υྫ ))
|
||
1,866,950 1,493,560 0.46% 0.52% September 18, 2026
|
||
Jiangmen Qishun
|
||
Technology
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(Ҧ
|
||
ΥྫΆุ
|
||
(Υྫ ))
|
||
1,493,350 1,493,350 0.46% 0.42% September 18, 2026
|
||
Faithful Way
|
||
Investment
|
||
Limited (༶
|
||
ʮ̡ )
|
||
1,183,540 1,183,540 0.36% 0.33% September 18, 2026
|
||
Nantong Ruiyi
|
||
Equity
|
||
Investment
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ᛆ
|
||
ҳ༟ΥྫΆุ
|
||
(Υྫ ))
|
||
933,470 466,735 0.14% 0.26% September 18, 2026
|
||
Hangzhou Yantong
|
||
Investment
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(ҳ༟
|
||
ΥྫΆุ
|
||
(Υྫ ))
|
||
581,310 581,310 0.18% 0.16% September 18, 2026
|
||
|
||
|
||
--- page 25 ---
|
||
25
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of
|
||
H Shares
|
||
held in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued
|
||
H Shares
|
||
after the
|
||
Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding
|
||
in the
|
||
Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Qingding (Beijing)
|
||
Management
|
||
Consulting
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
( Ꮧཻ(̏ԯ)၍ଣ
|
||
ፔ༔ΥྫΆุ
|
||
(Υྫ ))
|
||
112,230 112,230 0.03% 0.03% September 18, 2026
|
||
Shanghai
|
||
Shengcheng
|
||
Investment
|
||
Management
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
( ɪऎ໋ϓҳ༟
|
||
၍ଣΥྫΆุ
|
||
(Υྫ ))
|
||
88,910 44,455 0.01% 0.02% September 18, 2026
|
||
Subtotal 200,179,910 167,842,300 51.70% 56.08%
|
||
Notes:
|
||
(1) Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the
|
||
Over-allotment Option.
|
||
(2) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.
|
||
|
||
|
||
--- page 26 ---
|
||
26
|
||
Existing Shareholders (other than the Pre-IPO Investors as defined in the “History,
|
||
Development and Corporate Structure ” section of the Prospectus)
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of H
|
||
Shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
GenFleet
|
||
Therapeutics
|
||
(H.K.) Limited
|
||
( ೯ᖹุ (ಥ)
|
||
ʮ̡ ) 43,724,650 43,724,650 13.47% 12.25% September 18, 2026
|
||
Shanghai Kunjin
|
||
Consulting
|
||
Partnership
|
||
(Limited
|
||
Partnership)
|
||
(Άุ
|
||
၍ଣፔ༔Υྫ
|
||
Άุ(Υྫ )) 13,836,070 13,836,070 4.26% 3.88% September 18, 2026
|
||
Auspicious Delight
|
||
Limited 10,000,000 10,000,000 3.08% 2.80% September 18, 2026
|
||
Subtotal 67,560,720 67,560,720 20.81% 18.93%
|
||
Notes:
|
||
(1) Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the
|
||
Over-allotment Option.
|
||
(2) The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law.
|
||
(3) Each of Dr. Lu and Dr. Lan is a Warranting Shareholder as defined in the “Underwriting ” section of the
|
||
Prospectus. The lock-up requirement under the PRC Company Law is longer than the lock-up period in the
|
||
undertakings given by the Warranting Shareholders pursuant to the Hong Kong Underwriting Agreement.
|
||
Dr. Lu is deemed to be interested in (1) 13,836,070 H Shares through Shanghai Kunjin as its sole general
|
||
manager and (2) 53,724,650 H Shares through Auspicious Delight and GenFleet HK. Dr. Lan is deemed
|
||
to be interested in 53,724,650 H Shares through Auspicious Delight and GenFleet HK. For further details,
|
||
please refer to “Substantial Shareholders ” section of the Prospectus.
|
||
|
||
|
||
--- page 27 ---
|
||
27
|
||
Cornerstone Investors
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of H
|
||
Shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
RTW Master
|
||
Fund, Ltd.
|
||
3,054,200 3,054,200 0.94% 0.86% March 18, 2026
|
||
RTW Innovation
|
||
Master Fund,
|
||
Ltd.
|
||
2,444,400 2,444,400 0.75% 0.68% March 18, 2026
|
||
RTW Biotech
|
||
Opportunities
|
||
Operating Ltd.
|
||
236,600 236,600 0.07% 0.07% March 18, 2026
|
||
TruMed Health
|
||
Innovation
|
||
Fund LP
|
||
4,397,000 4,397,000 1.35% 1.23% March 18, 2026
|
||
TruMed Healthcare
|
||
Master Fund
|
||
382,200 382,200 0.12% 0.11% March 18, 2026
|
||
OrbiMed Genesis
|
||
Master
|
||
Fund, L.P.
|
||
1,903,000 1,903,000 0.59% 0.53% March 18, 2026
|
||
OrbiMed Partners
|
||
Master Fund
|
||
Limited
|
||
1,759,600 1,759,600 0.54% 0.49% March 18, 2026
|
||
The Biotech
|
||
Growth Trust
|
||
PLC
|
||
1,116,600 1,116,600 0.34% 0.31% March 18, 2026
|
||
UBS Asset
|
||
Management
|
||
(Singapore) Ltd.
|
||
3,823,400 3,823,400 1.18% 1.07% March 18, 2026
|
||
|
||
|
||
--- page 28 ---
|
||
28
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of H
|
||
Shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
Vivo Opportunity
|
||
Fund Holdings,
|
||
L.P.
|
||
3,472,800 3,472,800 1.07% 0.97% March 18, 2026
|
||
Vivo Opportunity
|
||
Caymen
|
||
Fund, L.P.
|
||
350,600 350,600 0.11% 0.10% March 18, 2026
|
||
China Universal
|
||
Asset
|
||
Management
|
||
(Hong Kong)
|
||
Company
|
||
Limited
|
||
3,058,800 3,058,800 0.94% 0.86% March 18, 2026
|
||
China Universal
|
||
Asset
|
||
Management
|
||
Company
|
||
Limited ( ි
|
||
΅
|
||
ʮ̡ )
|
||
764,600 764,600 0.24% 0.21% March 18, 2026
|
||
Fullgoal Fund
|
||
Management
|
||
Co., Ltd. ( బ
|
||
၍ଣ
|
||
ʮ̡ )
|
||
3,058,800 3,058,800 0.94% 0.86% March 18, 2026
|
||
Fullgoal Asset
|
||
Management
|
||
(HK) Limited
|
||
764,600 764,600 0.24% 0.21% March 18, 2026
|
||
CITIC Securities
|
||
International
|
||
Capital
|
||
Management
|
||
Limited (in
|
||
connection with
|
||
Tibet Longrising
|
||
OTC Swaps)
|
||
3,823,400 3,823,400 1.18% 1.07% March 18, 2026
|
||
|
||
|
||
--- page 29 ---
|
||
29
|
||
Name
|
||
Number of
|
||
shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
Number of H
|
||
Shares held in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing
|
||
% of total
|
||
issued H
|
||
Shares after
|
||
the Global
|
||
Offering
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
% of
|
||
shareholding in
|
||
the Company
|
||
subject to
|
||
lock-up
|
||
undertakings
|
||
upon Listing (1)
|
||
Last day subject
|
||
to the lock-up
|
||
undertakings (2)
|
||
LBC HK
|
||
Opportunity
|
||
Fund
|
||
1,533,200 1,533,200 0.47% 0.43% March 18, 2026
|
||
Lake Bleu Prime
|
||
Healthcare Fund
|
||
1,464,400 1,464,400 0.45% 0.41% March 18, 2026
|
||
Lake Bleu
|
||
Innovation Fund
|
||
825,800 825,800 0.25% 0.23% March 18, 2026
|
||
Subtotal 38,234,000 38,234,000 11.78% 10.71%
|
||
Notes:
|
||
(1) Taking into account the full exercise of the Offer Size Adjustment Option and before any exercise of the
|
||
Over-allotment Option.
|
||
(2) Each Cornerstone Investor shall not dispose of any of the Offer Shares acquired in the Global Offering at
|
||
any time during the period of six months following the Listing Date pursuant to their respective Cornerstone
|
||
Investment Agreement, save for certain limited circumstances, such as transfers to any of its wholly-owned
|
||
subsidiaries who will be bound by the same obligations of the relevant Cornerstone Investor, including the
|
||
lock-up period restriction. For details, please refer to the section headed “Cornerstone Investors – Restrictions
|
||
on the Cornerstone Investors ” of the Prospectus.
|
||
|
||
|
||
--- page 30 ---
|
||
30
|
||
PLACEE CONCENTRATION ANALYSIS
|
||
Placees
|
||
Number of
|
||
H Shares
|
||
allotted
|
||
Allotment as
|
||
% of
|
||
International
|
||
Offering
|
||
(assuming
|
||
no exercise
|
||
of the Over-
|
||
allotment
|
||
Option)
|
||
Allotment as
|
||
% of
|
||
International
|
||
Offering
|
||
(assuming the
|
||
Over- allotment
|
||
Option is
|
||
exercised and
|
||
new H Shares
|
||
are issued)
|
||
Allotment as
|
||
% of total
|
||
Offer Shares
|
||
(assuming
|
||
no exercise
|
||
of the Over-
|
||
allotment
|
||
Option)
|
||
Allotment as %
|
||
of total Offer
|
||
Shares
|
||
(assuming the
|
||
Over-allotment
|
||
Option is
|
||
exercised and
|
||
new H Shares
|
||
are issued)
|
||
Number of
|
||
Shares
|
||
held upon
|
||
Listing
|
||
% of total
|
||
issued
|
||
share capital
|
||
upon Listing
|
||
(assuming no
|
||
exercise of
|
||
the Over-
|
||
allotment
|
||
Option)
|
||
% of total
|
||
issued share
|
||
capital upon
|
||
Listing
|
||
(assuming the
|
||
Over-allotment
|
||
Option is
|
||
exercised and
|
||
new H Shares
|
||
are issued)
|
||
Top 1 5,735,200 7.04% 6.05% 6.43% 5.59% 5,735,200 1.61% 1.55%
|
||
Top 5 24,082,000 29.56% 25.39% 26.99% 23.47% 24,082,000 6.75% 6.50%
|
||
Top 10 43,575,600 53.48% 45.93% 48.83% 42.46% 46,515,840 13.03% 12.56%
|
||
Top 25 72,938,400 89.52% 76.89% 81.73% 71.07% 110,824,480 31.04% 29.92%
|
||
Notes
|
||
* Ranking of placees is based on the number of H Shares allotted to the placees.
|
||
H SHAREHOLDERS CONCENTRATION ANALYSIS
|
||
H
|
||
Shareholders*
|
||
Number of
|
||
H Shares
|
||
allotted
|
||
Allotment as
|
||
% of
|
||
International
|
||
Offering
|
||
(assuming
|
||
no exercise
|
||
of the Over-
|
||
allotment
|
||
Option)
|
||
Allotment as
|
||
% of
|
||
International
|
||
Offering
|
||
(assuming
|
||
the Over-
|
||
allotment
|
||
Option is
|
||
exercised
|
||
and new H
|
||
Shares are
|
||
issued)
|
||
Allotment
|
||
as % of
|
||
total Offer
|
||
Shares
|
||
(assuming
|
||
no
|
||
exercise
|
||
of the Over-
|
||
allotment
|
||
Option)
|
||
Allotment
|
||
as % of
|
||
total Offer
|
||
Shares
|
||
(assuming
|
||
the Over-
|
||
allotment
|
||
Option is
|
||
exercised
|
||
and new
|
||
H Shares
|
||
are issued)
|
||
Number of
|
||
H Shares
|
||
held upon
|
||
Listing
|
||
% of total
|
||
issued H
|
||
Shares
|
||
capital
|
||
upon
|
||
Listing
|
||
(assuming
|
||
no exercise
|
||
of the Over-
|
||
allotment
|
||
Option)
|
||
% of total
|
||
issued H
|
||
Shares
|
||
capital
|
||
upon
|
||
Listing
|
||
(assuming
|
||
the Over-
|
||
allotment
|
||
Option is
|
||
exercised
|
||
and new
|
||
H Shares
|
||
are issued)
|
||
Number of
|
||
Shares
|
||
held upon
|
||
Listing
|
||
Top 1 0 0.00% 0.00% 0.00% 0.00% 67,560,720 20.81% 19.99% 67,560,720
|
||
Top 5 1,720,200 2.11% 1.81% 1.93% 1.68% 132,179,530 40.72% 39.10% 132,179,530
|
||
Top 10 3,631,200 4.46% 3.83% 4.07% 3.54% 176,797,350 54.46% 52.30% 176,797,350
|
||
Top 25 42,242,800 51.84% 44.53% 47.34% 41.16% 252,603,735 77.81% 74.73% 257,341,810
|
||
Notes
|
||
* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.
|
||
|
||
|
||
--- page 31 ---
|
||
31
|
||
SHAREHOLDER CONCENTRATION ANALYSIS
|
||
Shareholders
|
||
Number of
|
||
H Shares
|
||
allotted
|
||
Allotment as
|
||
% of
|
||
International
|
||
Offering
|
||
(assuming
|
||
no exercise
|
||
of the Over-
|
||
allotment
|
||
Option)
|
||
Allotment as
|
||
% of
|
||
International
|
||
Offering
|
||
(assuming
|
||
the Over-
|
||
allotment
|
||
Option is
|
||
exercised
|
||
and new
|
||
H Shares
|
||
are issued)
|
||
Allotment
|
||
as % of
|
||
total Offer
|
||
Shares
|
||
(assuming
|
||
no exercise
|
||
of the Over-
|
||
allotment
|
||
Option)
|
||
Allotment
|
||
as % of
|
||
total Offer
|
||
Shares
|
||
(assuming
|
||
the Over-
|
||
allotment
|
||
Option is
|
||
exercised
|
||
and new
|
||
H Shares
|
||
are issued)
|
||
Number of
|
||
H Shares
|
||
held upon
|
||
Listing
|
||
Number of
|
||
Shares
|
||
held upon
|
||
Listing
|
||
% of total
|
||
issued share
|
||
capital upon
|
||
Listing
|
||
(assuming
|
||
no exercise
|
||
of the Over-
|
||
allotment
|
||
Option)
|
||
% of total
|
||
issued share
|
||
capital upon
|
||
Listing
|
||
(assuming
|
||
the Over-
|
||
allotment
|
||
Option is
|
||
exercised
|
||
and new
|
||
H Shares
|
||
are issued)
|
||
Top 1 0 0.00% 0.00% 0.00% 0.00% 67,560,720 67,560,720 18.93% 18.24%
|
||
Top 5 1,720,200 2.11% 1.81% 1.93% 1.68% 121,726,060 134,897,880 37.79% 36.42%
|
||
Top 10 3,631,200 4.46% 3.83% 4.07% 3.54% 165,306,095 183,215,990 51.32% 49.47%
|
||
Top 25 34,219,400 42.00% 36.07% 38.35% 33.34% 242,739,495 267,412,500 74.91% 72.20%
|
||
Notes
|
||
* Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.
|
||
|
||
|
||
--- page 32 ---
|
||
32
|
||
BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING
|
||
Subject to the satisfaction of the conditions set out in the Prospectus, a total of 257,876 valid
|
||
applications made by the public will be conditionally allocated on the basis set out below:
|
||
NO. OF SHARES
|
||
APPLIED FOR
|
||
NO. OF VALID
|
||
APPLICATIONS BASIS OF ALLOTMENT/BALLOT
|
||
APPROXIMATE
|
||
PERCENTAGE
|
||
ALLOTTED OF
|
||
THE TOTAL
|
||
NO. OF SHARES
|
||
APPLIED FOR
|
||
POOL A
|
||
200 56,508 46 out of 56,508 to receive 200 Shares 0.08%
|
||
400 23,969 39 out of 23,969 to receive 200 Shares 0.08%
|
||
600 9,645 24 out of 9,645 to receive 200 Shares 0.08%
|
||
800 6,303 21 out of 6,303 to receive 200 Shares 0.08%
|
||
1,000 8,391 35 out of 8,391 to receive 200 Shares 0.08%
|
||
1,200 3,616 18 out of 3,616 to receive 200 Shares 0.08%
|
||
1,400 2,793 16 out of 2,793 to receive 200 Shares 0.08%
|
||
1,600 2,412 16 out of 2,412 to receive 200 Shares 0.08%
|
||
1,800 2,148 16 out of 2,148 to receive 200 Shares 0.08%
|
||
2,000 18,966 156 out of 18,966 to receive 200 Shares 0.08%
|
||
3,000 7,485 92 out of 7,485 to receive 200 Shares 0.08%
|
||
4,000 8,121 134 out of 8,121 to receive 200 Shares 0.08%
|
||
5,000 5,633 116 out of 5,633 to receive 200 Shares 0.08%
|
||
6,000 3,659 90 out of 3,659 to receive 200 Shares 0.08%
|
||
7,000 2,727 79 out of 2,727 to receive 200 Shares 0.08%
|
||
8,000 2,718 89 out of 2,718 to receive 200 Shares 0.08%
|
||
9,000 2,595 96 out of 2,595 to receive 200 Shares 0.08%
|
||
10,000 15,251 627 out of 15,251 to receive 200 Shares 0.08%
|
||
20,000 10,301 847 out of 10,301 to receive 200 Shares 0.08%
|
||
30,000 5,947 734 out of 5,947 to receive 200 Shares 0.08%
|
||
40,000 4,988 821 out of 4,988 to receive 200 Shares 0.08%
|
||
50,000 4,208 865 out of 4,208 to receive 200 Shares 0.08%
|
||
60,000 2,901 716 out of 2,901 to receive 200 Shares 0.08%
|
||
70,000 2,410 694 out of 2,410 to receive 200 Shares 0.08%
|
||
80,000 1,974 650 out of 1,974 to receive 200 Shares 0.08%
|
||
90,000 1,763 653 out of 1,763 to receive 200 Shares 0.08%
|
||
100,000 6,372 2,621 out of 6,372 to receive 200 Shares 0.08%
|
||
150,000 4,417 2,725 out of 4,417 to receive 200 Shares 0.08%
|
||
200,000 7,738 6,364 out of 7,738 to receive 200 Shares 0.08%
|
||
235,959 Total number of Pool A successful applicants: 19,400
|
||
|
||
|
||
--- page 33 ---
|
||
33
|
||
NO. OF SHARES
|
||
APPLIED FOR
|
||
NO. OF VALID
|
||
APPLICATIONS BASIS OF ALLOTMENT/BALLOT
|
||
APPROXIMATE
|
||
PERCENTAGE
|
||
ALLOTTED OF
|
||
THE TOTAL
|
||
NO. OF SHARES
|
||
APPLIED FOR
|
||
POOL B
|
||
250,000 4,430 1,348 out of 4,430 to receive 200 Shares 0.02%
|
||
300,000 2,398 875 out of 2,398 to receive 200 Shares 0.02%
|
||
350,000 1,868 795 out of 1,868 to receive 200 Shares 0.02%
|
||
400,000 1,702 828 out of 1,702 to receive 200 Shares 0.02%
|
||
450,000 1,250 684 out of 1,250 to receive 200 Shares 0.02%
|
||
500,000 1,935 1,177 out of 1,935 to receive 200 Shares 0.02%
|
||
600,000 1,379 1,007 out of 1,379 to receive 200 Shares 0.02%
|
||
700,000 964 821 out of 964 to receive 200 Shares 0.02%
|
||
800,000 770 749 out of 770 to receive 200 Shares 0.02%
|
||
900,000 678 200 Shares plus 64 out of 678 to receive
|
||
additional 200 Shares
|
||
0.02%
|
||
1,000,000 1,838 200 Shares plus 398 out of 1,838 to receive
|
||
additional 200 Shares
|
||
0.02%
|
||
1,500,000 885 200 Shares plus 730 out of 885 to receive
|
||
additional 200 Shares
|
||
0.02%
|
||
2,000,000 556 400 Shares plus 241 out of 556 to receive
|
||
additional 200 Shares
|
||
0.02%
|
||
2,500,000 281 600 Shares plus 12 out of 281 to receive
|
||
additional 200 Shares
|
||
0.02%
|
||
3,000,000 304 600 Shares plus 198 out of 304 to receive
|
||
additional 200 Shares
|
||
0.02%
|
||
3,880,000 679 800 Shares plus 489 out of 679 to receive
|
||
additional 200 Shares
|
||
0.02%
|
||
21,917 Total number of Pool B successful applicants: 13,505
|
||
|
||
|
||
--- page 34 ---
|
||
34
|
||
As of the date of this announcement, the relevant subscription monies previously deposited in the
|
||
designated nominee accounts have been remitted back to the accounts of all HKSCC participants.
|
||
Investors should contact their relevant brokers for any inquiries.
|
||
COMPLIANCE WITH LISTING RULES AND GUIDANCE
|
||
The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of
|
||
which consent has been obtained, the Company has complied with the Listing Rules and guidance
|
||
materials in relation to the placing, allotment and listing of the Company ’s H Shares.
|
||
The Directors confirm that, to the best of their knowledge, no rebate has been, directly or
|
||
indirectly, provided by the Company, its controlling shareholder(s), directors or syndicate members
|
||
to any placees or the public (as the case may be) and the consideration payable by them for each
|
||
Offer Share of the Company subscribed for or purchased by them is the same as the Offer Price
|
||
determined by the Company, in addition to any brokerage, AFRC transaction levy, SFC transaction
|
||
levy and trading fee payable.
|
||
OTHER INFORMATION
|
||
Offer Size Adjustment Option
|
||
The Offer Size Adjustment Option has been fully exercised by the Sole Sponsor-Overall
|
||
Coordinator, pursuant to which the Company is issuing and allotting 11,640,000 additional Offer
|
||
Shares, representing approximately 15% of the total number of Offer Shares initially available
|
||
under the Global Offering, at the Offer Price. All of the additional Offer Shares that would be
|
||
allotted and issued by the Company pursuant to the full exercise of the Offer Size Adjustment
|
||
Option will be allocated to the International Offering. Accordingly, the total number of Offer
|
||
Shares finally available under the Global Offering (taking into account the full exercise of the
|
||
Offer Size Adjustment Option and before any exercise of the Over-allotment Option) that would be
|
||
allotted and issued by the Company is 89,240,000 Offer Shares and the total issued share capital
|
||
of the Company upon Listing (taking into account the full exercise of the Offer Size Adjustment
|
||
Option and before any exercise of the Over-allotment Option) will be 356,980,630 Shares.
|
||
As a result of the above, the final number of Offer Shares under the International Offering is
|
||
adjusted to 81,480,000 Shares, representing approximately 91.30% of the total number of Offer
|
||
Shares under the Global Offering (assuming the Over-allotment Option is not exercised).
|
||
|
||
|
||
--- page 35 ---
|
||
35
|
||
Placing to existing Shareholders and/or their close associates with prior consent under
|
||
paragraph 1C(2) of the Placing Guidelines
|
||
Lake Bleu Prime Healthcare Master Fund Limited, Lake Bleu Innovation Healthcare
|
||
Master Fund Limited, and LBC HK Opportunity Fund Limited (collectively, the “Lake Bleu
|
||
Entities ”)
|
||
The Company has applied to the Stock Exchange, and the Stock Exchange has granted, a consent
|
||
under paragraph 1C(2) of the Placing Guidelines to permit the Company to allocate such Offer
|
||
Shares in the International Offering to the Lake Bleu Entities, each a close associate of an existing
|
||
Shareholder, LBC Sunshine Healthcare Fund II L.P.. Please refer to the section headed “Waivers
|
||
and Exemption – Consent in respect of Cornerstone Investment by Close Associates of Minority
|
||
Existing Shareholder ” in the Prospectus for details.
|
||
GF International, Value Partners, E Fund Management, E Fund HK, Five Investment and
|
||
Apricot BioScience (collectively, the “Close Associates of Existing Shareholders as Placees ”)
|
||
The Company has applied to the Stock Exchange, and the Stock Exchange has granted a consent
|
||
under paragraph 1C(2) of the Placing Guidelines to permit the Company to allocate such Offer
|
||
Shares in the International Offering to the Close Associates of Existing Shareholders as Placees.
|
||
Each of GF International, Value Partners, E Fund Management and E Fund HK is a close associate
|
||
of GF Qianhe, an existing Shareholder of the Company. Five Investment is a close associate of
|
||
Ourea Biotech, an existing Shareholder of the Company. Apricot BioScience is a close associate
|
||
of Suzhou Apricot, an existing Shareholder of the Company. The allocation of Offer Shares to the
|
||
Close Associates of Existing Shareholders as Placees is in compliance with all the conditions under
|
||
the consent granted by the Stock Exchange, including but not limited to (i) the Company complies
|
||
with Rules 19A.13A and 19A.13C of the Listing Rules, and (ii) no preference in allocation was
|
||
given to the Close Associates of Existing Shareholders as Placees.
|
||
For details of the allocations of Offer Shares to close associates of existing Shareholders, please
|
||
refer to the section headed “Allotment Results Details { International Offering { Allotees with
|
||
Waivers/Consents Obtained ” in this announcement.
|
||
Placing to connected clients with prior consent under paragraph 1C(1) of the Placing
|
||
Guidelines
|
||
The Company has applied to the Stock Exchange for, and the Stock Exchange has granted a
|
||
consent under paragraph 1C(1) of the Placing Guidelines to permit CITIC Securities International
|
||
Capital Management Limited (in connection with Tibet Longrising OTC Swaps) to participate
|
||
in the Global Offering as a Cornerstone Investor. Please refer to the section headed “Waivers
|
||
and Exemption { Consent in respect of Cornerstone Investment by Connected Client ” in the
|
||
Prospectus for details.
|
||
|
||
|
||
--- page 36 ---
|
||
36
|
||
In addition, the Company has applied to the Stock Exchange, and the Stock Exchange has granted, a consent under paragraph 1C(1)
|
||
of the Placing Guidelines to permit the Company to allocate certain Offer Shares in the International Offering to connected clients as
|
||
placees. The allocation of Offer Shares to such connected clients is in compliance with all the conditions under the consent granted by
|
||
the Stock Exchange. Details of the placement to the connected clients are set out below.
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
1. GF International GF Securities
|
||
(Hong Kong)
|
||
Brokerage,
|
||
one of the
|
||
distributors
|
||
of the Global
|
||
Offering.
|
||
GF International is a
|
||
member of the same
|
||
group of companies
|
||
as GF Securities
|
||
(Hong Kong)
|
||
Brokerage.
|
||
Discretionary 1,145,000 GF International will hold the Offer Shares in its capacity as
|
||
the discretionary fund manager managing the following funds
|
||
on behalf of their underlying clients, each of which is an
|
||
independent third party:
|
||
1. GF INTERNATIONAL INVESTMENT MANAGEMENT
|
||
LTD-CLIENTS ’AC GF NAVIGATOR: the ultimate
|
||
beneficial owner holding 30% or more interest therein is
|
||
Lavender Paul ANDREW;
|
||
2. GF INTERNATIONAL INVESTMENT MANAGEMENT
|
||
LIMITED – YPZ: the ultimate beneficial owner holding
|
||
30% or more interest therein is Yu Pei Zhong (); and
|
||
3. GF INTERNATIONAL INVESTMENT MANAGEMENT
|
||
LIMITED – MWBCL: the ultimate beneficial owner holding
|
||
30% or more interest therein is Qin Tianyu ( ॢ˂ρ).
|
||
1.283% 0.321%
|
||
|
||
|
||
--- page 37 ---
|
||
37
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
2. Value Partners Value Partners is a
|
||
member of the same
|
||
group of companies
|
||
as GF Securities
|
||
(Hong Kong)
|
||
Brokerage.
|
||
Discretionary 8,800 Value Partners will hold the Offer Shares in its capacity as the
|
||
discretionary fund manager managing SFC-authorized and non-
|
||
SFC-authorized collective investment schemes on behalf its
|
||
underlying clients, each of which is an independent third party.
|
||
The ultimate beneficial owners holding 30% or more interest in
|
||
the SFC-authorized collective investment schemes are set out
|
||
below, all of which belong to listed financial groups:
|
||
1. AIA INTERNATIONAL LIMITED – ASSET LIFE PLAN
|
||
2. THE MASTER TRUST BANK OF JAPAN.LTD.
|
||
3. BANK OF CHINA (HONG KONG) NOMINEES LIMITED
|
||
Please refer to note 1 for the details of the non-SFC-authorized
|
||
collective investment funds. Their ultimate beneficial owners
|
||
are as below:
|
||
1. Value Partners Funds SPC – Value Partners China A-Share
|
||
Innovation Fund SP: the ultimate beneficial owner holding
|
||
30% or more interest therein is Custody Bank of Japan, Ltd.
|
||
2. Value Partners Intelligent Funds – JA-VP China New
|
||
Century Fund: the ultimate beneficial owner holding 30% or
|
||
more interest therein is Aizawa Securities Co., Ltd.
|
||
0.010% 0.002%
|
||
|
||
|
||
--- page 38 ---
|
||
38
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
3. E Fund Hong
|
||
Kong
|
||
E Fund Management
|
||
and E Fund Hong
|
||
Kong are members
|
||
of the same group
|
||
of companies as GF
|
||
Securities (Hong
|
||
Kong) Brokerage.
|
||
Discretionary 104,000 E Fund Hong Kong will hold the Offer Shares in its capacity
|
||
as the discretionary fund manager managing on behalf of its
|
||
underlying clients, each of which is independent from each
|
||
of the Company, its subsidiaries, its Single Largest Group of
|
||
Shareholders (as defined in the Prospectus) or its substantial
|
||
shareholders to the best knowledge and belief and after due
|
||
enquiry of E Fund Hong Kong.
|
||
The information of the funds are set out below:
|
||
1. E Fund (HK) Global Quality Growth Fund: The ultimate
|
||
beneficial owner holding 30% or more interest is
|
||
Clearstream Banking S.A., a central securities depository.
|
||
2. E Fund (HK) China Equity Dividend Fund: no ultimate
|
||
beneficial owner holds 30% or more interest therein.
|
||
0.12% 0.03%
|
||
4. E Fund
|
||
Management
|
||
Discretionary 1,425,000 E Fund Management will hold the Offer Shares in its capacity
|
||
as the discretionary fund manager managing the funds on
|
||
behalf of its underlying clients, each of which is an independent
|
||
third party to the best knowledge and belief and after due
|
||
enquiry of E Fund Management. No ultimate beneficial owner
|
||
holds 30% or more interest in any of the underlying clients.
|
||
1.60% 0.40%
|
||
|
||
|
||
--- page 39 ---
|
||
39
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
5. CSICM (in
|
||
connection
|
||
with Beijing
|
||
Heyiyingtong
|
||
OTC Swaps)
|
||
CLSA, one of
|
||
the Overall
|
||
Coordinators
|
||
of the Global
|
||
Offering
|
||
CSICM, CITICS and
|
||
CLSA are members
|
||
of the same group of
|
||
companies.
|
||
Non-discretionary
|
||
on behalf of
|
||
independent
|
||
third parties
|
||
3,800 CSICM and CITIC Securities Company Limited ( “CITICS ”)
|
||
will enter into a series of cross border OTC swap transactions
|
||
(“Beijing Heyiyingtong OTC Swaps ”) with Beijing
|
||
Heyiyingtong Asset Management Co., Ltd. (ޮ
|
||
ʮ̡ ) (“Beijing Heyiyingtong ”), as the
|
||
investment manager for and on behalf of certain ultimate
|
||
clients (collectively, the “Beijing Heyiyingtong Ultimate
|
||
Clients ”), pursuant to which CSICM will hold the Offer Shares
|
||
to be subscribed for and on behalf of Beijing Heyiyingtong on
|
||
a non-discretionary basis to hedge the Beijing Heyiyingtong
|
||
OTC Swaps while the economic risks and returns of the
|
||
underlying Offer Shares are passed to the Beijing Heyiyingtong
|
||
Ultimate Clients, subject to customary fees and commissions.
|
||
CSICM will not take part in any economic returns or bear any
|
||
economic losses in relation to the Offer Shares. The Beijing
|
||
Heyiyingtong OTC Swaps will be fully funded by the Beijing
|
||
Heyiyingtong Ultimate Clients.
|
||
0.004% 0.001%
|
||
|
||
|
||
--- page 40 ---
|
||
40
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
CSICM undertakes that it will not exercise any voting rights
|
||
attached to the Offer Shares.
|
||
Each of the Beijing Heyiyingtong Ultimate Clients are either
|
||
an investment fund and/or management product managed
|
||
by Beijing Heyiyingtong. The ultimate beneficial owners of
|
||
Beijing Heyiyingtong are Liu Zhe ( ᄎ䂮) and Liu Yang (ݱ.)
|
||
Beijing Heyiyingtong is an asset management company based
|
||
in Beijing, China, focusing on equity investments in emerging
|
||
industries and healthcare sectors, with exposure to the Hong
|
||
Kong and mainland China capital markets.
|
||
It is submitted that, pursuant to the confirmation of Beijing
|
||
Heyiyingtong, each of Beijing Heyiyingtong and its ultimate
|
||
beneficial owner is independent from each of the Company, its
|
||
subsidiaries and substantial Shareholders.
|
||
No single ultimate beneficial owner holds 30% or more
|
||
interests in any of the Beijing Heyiyingtong Ultimate Clients.
|
||
|
||
|
||
--- page 41 ---
|
||
41
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
To the best knowledge of CSICM after making all reasonable
|
||
enquiries, each of the Beijing Heyiyingtong Ultimate
|
||
Clients and their respective ultimate beneficial owners is
|
||
an independent third party of (i) CSICM, CLSA and the
|
||
companies which are members of the same group of CLSA and
|
||
(ii) the Company, its subsidiaries, the Single Largest Group of
|
||
Shareholders (as defined in the Prospectus) and its substantial
|
||
Shareholders.
|
||
6. CSICM (in
|
||
connection
|
||
wtih HY
|
||
Capital OTW
|
||
Swaps)
|
||
CLSA CSICM, CITICS and
|
||
CLSA are members
|
||
of the same group of
|
||
companies.
|
||
Non-discretionary
|
||
on behalf of
|
||
independent
|
||
third parties
|
||
229,400 CSICM and CITICS will enter into a series of cross border
|
||
OTC swap transactions ( “HY Capital OTC Swaps ”) with HY
|
||
Capital Company Limited ( “HY Capital ”), pursuant to which
|
||
CSICM will hold the Offer Shares to be subscribed for and on
|
||
behalf of HY Capital on a non-discretionary basis to hedge the
|
||
HY Capital OTC Swaps while the economic risks and returns
|
||
of the underlying Offer Shares are passed to HY Capital,
|
||
subject to customary fees and commissions. CSICM will not
|
||
take part in any economic returns or bear any economic losses
|
||
in relation to the Offer Shares. CSICM undertakes that it will
|
||
not exercise any voting rights attached to the Offer Shares.
|
||
0.257% 0.064%
|
||
|
||
|
||
--- page 42 ---
|
||
42
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
HY Capital is an investment company focusing on equity and
|
||
alternative investments, with particular interest in emerging
|
||
markets and the healthcare sector, including opportunities in
|
||
the Hong Kong capital market. The ultimate beneficial owners
|
||
of HY Capital are Xia Hui and Lu Ang.
|
||
To the best knowledge of CSICM after making all reasonable
|
||
enquiries, HY Capital and its respective ultimate beneficial
|
||
owners is an independent third party of (i) CSICM, CLSA and
|
||
the companies which are members of the same group of CLSA
|
||
and (ii) the Company, its subsidiaries, the Single Largest
|
||
Group of Shareholders (as defined in the Prospectus) and its
|
||
substantial Shareholders.
|
||
|
||
|
||
--- page 43 ---
|
||
43
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
7. CSICM (in
|
||
connection
|
||
with Shanghai
|
||
Panjing OTC
|
||
Swaps)
|
||
CLSA CSICM, CITICS and
|
||
CLSA are members
|
||
of the same group of
|
||
companies.
|
||
Non-discretionary
|
||
on behalf of
|
||
independent third
|
||
parties
|
||
573,400 CSICM and CITICS will enter into a series of cross border
|
||
OTC swap transactions ( “Shanghai Panjing OTC Swaps ”)
|
||
with Shanghai Panjing Investment Management Center
|
||
(Limited Partnership) ( ɪऎᆵԯҳ༟၍ଣʕː (Υྫ ))
|
||
(the “Shanghai Panjing ”), as the investment manager for
|
||
and on behalf of certain ultimate clients (collectively, the
|
||
“Shanghai Panjing Ultimate Clients ”), pursuant to which
|
||
CSICM will hold the Offer Shares to be subscribed for and on
|
||
behalf of the Shanghai Panjing on a non-discretionary basis to
|
||
hedge the Shanghai Panjing OTC Swaps while the economic
|
||
risks and returns of the underlying Offer Shares are passed to
|
||
Shanghai Panjing, subject to customary fees and commissions.
|
||
CSICM will not take part in any economic returns or bear any
|
||
economic losses in relation to the Offer Shares. The Shanghai
|
||
Panjing OTC Swaps will be fully funded by Shanghai Panjing.
|
||
CSICM undertakes that it will not exercise any voting rights
|
||
attached to the Offer Shares.
|
||
The Shanghai Panjing Ultimate Clients are 71 investment funds
|
||
and/or management products managed by Shanghai Panjing.
|
||
The ultimate beneficial owner of Shanghai Panjing is Zhuang
|
||
Tao ( ᏹ).
|
||
0.643% 0.161%
|
||
|
||
|
||
--- page 44 ---
|
||
44
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
Shanghai Panjing is an asset management company based in
|
||
Shanghai, China, focusing on equity investments in emerging
|
||
industries and healthcare sectors, with exposure to the Hong
|
||
Kong and mainland China capital markets.
|
||
It is submitted that, pursuant to the confirmation of the
|
||
Shanghai Panjing, each of Shanghai Panjing and its ultimate
|
||
beneficial owner is independent from each of the Company, its
|
||
subsidiaries and substantial shareholders.
|
||
The ultimate beneficial owners holding 30% or more interests
|
||
in each of the Shanghai Panjing Ultimate Clients are Li
|
||
Ruxiang ( ҽνୂ) (in one Shanghai Panjing Ultimate Client)
|
||
and Zhuang Tao ( ᏹ) (in seven Shanghai Panjing Ultimate
|
||
Clients). There is no ultimate beneficial owner holding 30% or
|
||
more interests in the other Shanghai Panjing Ultimate Clients.
|
||
To the best knowledge of CSICM after making all reasonable
|
||
enquiries, each of the Shanghai Panjing Ultimate Clients and
|
||
their respective ultimate beneficial owners is an independent
|
||
third party of (i) CSICM, CLSA and the companies which are
|
||
members of the same group of CLSA and (ii) the Company,
|
||
its subsidiaries, the Single Largest Group of Shareholders (as
|
||
defined in the Prospectus) and its substantial shareholders.
|
||
|
||
|
||
--- page 45 ---
|
||
45
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
8. CSICM (in
|
||
connection
|
||
with Shanghai
|
||
Juming OTC
|
||
Swaps)
|
||
CLSA CSICM, CITICS and
|
||
CLSA are members
|
||
of the same group of
|
||
companies.
|
||
Non-discretionary
|
||
on behalf of
|
||
independent third
|
||
parties
|
||
400 CSICM and CITICS will enter into a series of cross border
|
||
OTC swap transactions ( “Shanghai Juming OTC Swaps ”)
|
||
with Shanghai Juming Investment Management Co., Ltd. ( ɪऎ
|
||
ʮ̡ ) (“Shanghai Juming “), pursuant to
|
||
which CSICM will hold the Offer Shares to be subscribed for
|
||
and on behalf of Shanghai Juming on a non-discretionary basis
|
||
to hedge the Shanghai Juming OTC Swaps while the economic
|
||
risks and returns of the underlying Offer Shares are passed to
|
||
Shanghai Juming, subject to customary fees and commissions.
|
||
CSICM will not take part in any economic returns or bear any
|
||
economic losses in relation to the Offer Shares. The Shanghai
|
||
Juming OTC Swaps will be fully funded by Shanghai Juming.
|
||
CSICM undertakes that it will not exercise any voting rights
|
||
attached to the Offer Shares.
|
||
The ultimate clients of Shanghai Juming are 37 investment
|
||
funds and/or management products managed by Shanghai
|
||
Juming (the “Shanghai Juming Ultimate Clients ”). The
|
||
ultimate beneficial owner of Shanghai Juming is Liu Xiaolong
|
||
(ᄎወᎲ).
|
||
0.0004% 0.0001%
|
||
|
||
|
||
--- page 46 ---
|
||
46
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
Shanghai Juming is an asset management company based in
|
||
Shanghai, China, focusing on equity investments in emerging
|
||
industries and healthcare sectors, with exposure to the Hong
|
||
Kong and mainland China capital markets.
|
||
The ultimate beneficial owners holding 30% or more interests
|
||
in each of the Shanghai Juming Ultimate Clients are Liu
|
||
Xiaolong ( ᄎወᎲ) (in two Shanghai Juming Ultimate Clients),
|
||
Wang Tingting ( ˮణణ) (in two Shanghai Junming Ultimate
|
||
Clients), Wang Wenxiang ( ˮ˖ୂ) (in one Shanghai Junming
|
||
Ultimate Client), Fang Ge (ࣸin one Shanghai Junming
|
||
Ultimate Client), Wang Manqiong ( ˮਟᖘ) (in one Shanghai
|
||
Junming Ultimate Client) and Wei Si (ܠࠨin one Shanghai
|
||
Junming Ultimate Client). There is no ultimate beneficial
|
||
owner holding 30% or more interests in the other Shanghai
|
||
Juming Ultimate Clients.
|
||
To the best knowledge of CSICM after making all reasonable
|
||
enquiries, Shanghai Juming and its respective ultimate
|
||
beneficial owners is an independent third party of (i) CSICM,
|
||
CLSA and the companies which are members of the same
|
||
group of CLSA and (ii) the Company, its subsidiaries, the
|
||
Single Largest Group of Shareholders (as defined in the
|
||
Prospectus) and its substantial Shareholders.
|
||
|
||
|
||
--- page 47 ---
|
||
47
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
9. CSICM (in
|
||
connection
|
||
with Shenzhn
|
||
Hongchou OTC
|
||
Swaps)
|
||
CSICM, CITICS and
|
||
CLSA are members
|
||
of the same group of
|
||
companies.
|
||
Non-discretionary
|
||
on behalf of
|
||
independent third
|
||
parties
|
||
305,600 CSICM and CITICS will enter into a series of cross border
|
||
OTC swap transactions ( “Shenzhen Hongchou OTC Swaps ”)
|
||
with Shenzhen Hongchou Investment Co., Ltd. (ᘪ
|
||
ʮ̡ ) (“Shenzhen Hongchou ”), as the investment
|
||
manager for and on behalf of certain ultimate clients
|
||
(collectively, the “Shenzhen Hongchou Ultimate Clients ”),
|
||
pursuant to which CSICM will hold the Offer Shares to be
|
||
subscribed for and on behalf of the Shenzhen Hongchou on a
|
||
non-discretionary basis to hedge the Shenzhen Hongchou OTC
|
||
Swaps while the economic risks and returns of the underlying
|
||
Offer Shares are passed to Shenzhen Hongchou, subject to
|
||
customary fees and commissions. CSICM will not take part in
|
||
any economic returns or bear any economic losses in relation
|
||
to the Offer Shares. The Shenzhen Hongchou OTC Swaps will
|
||
be fully funded by Shenzhen Hongchou. CSICM undertakes
|
||
that it will not exercise any voting rights attached to the Offer
|
||
Shares.
|
||
0.342% 0.086%
|
||
|
||
|
||
--- page 48 ---
|
||
48
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
The Shenzhen Hongchou Ultimate Clients are 15 investment
|
||
funds and/or management products managed by Shenzhen
|
||
Hongchou. The ultimate beneficial owner of Shenzhen
|
||
Hongchou is Tang Liang (ڥࡥ.)
|
||
No ultimate beneficial owner holds 30% or more interests in
|
||
each of the Shenzhen Hongchou Ultimate Clients.
|
||
To the best knowledge of CSICM after making all reasonable
|
||
enquiries, each of the Shenzhen Hongchou Ultimate Clients and
|
||
their respective ultimate beneficial owners is an independent
|
||
third party of (i) CSICM, CLSA and the companies which are
|
||
members of the same group of CLSA and (ii) the Company,
|
||
its subsidiaries, the Single Largest Group of Shareholders (as
|
||
defined in the Prospectus) and its substantial shareholders.
|
||
|
||
|
||
--- page 49 ---
|
||
49
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
10. CSICM (in
|
||
connection
|
||
with Shanghai
|
||
PinPoint OTC
|
||
Swaps)
|
||
CSICM, CITICS and
|
||
CLSA are members
|
||
of the same group of
|
||
companies.
|
||
Non-discretionary
|
||
on behalf of
|
||
independent third
|
||
parties
|
||
400 CSICM and CITICS will enter into a series of cross border
|
||
OTC swap transactions ( “Shanghai Pinpoint OTC Swaps ”)
|
||
with Shanghai PinPoint Private Equity Fund Management
|
||
Co., Ltd. (ʮ̡ ) (“Shanghai
|
||
Pinpoint ”), as the investment manager for and on behalf of
|
||
certain ultimate clients (collectively, the “Shanghai Pinpoint
|
||
Ultimate Clients ”), pursuant to which CSICM will hold the
|
||
Offer Shares to be subscribed for and on behalf of the Shanghai
|
||
Pinpoint on a non-discretionary basis to hedge the Shanghai
|
||
Pinpoint OTC Swaps while the economic risks and returns of
|
||
the underlying Offer Shares are passed to Shanghai Pinpoint,
|
||
subject to customary fees and commissions. CSICM will not
|
||
take part in any economic returns or bear any economic losses
|
||
in relation to the Offer Shares. The Shanghai Pinpoint OTC
|
||
Swaps will be fully funded by Shanghai Pinpoint. CSICM
|
||
undertakes that it will not exercise any voting rights attached
|
||
to the Offer Shares.
|
||
0.0004% 0.0001%
|
||
|
||
|
||
--- page 50 ---
|
||
50
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
The Shanghai Pinpoint Ultimate Clients are 3 investment
|
||
funds and/or management products managed by the Shanghai
|
||
Pinpoint. The ultimate beneficial owner of Shanghai Pinpoint
|
||
is Li Mo ( ҽኈ).
|
||
Shanghai Pinpoint is an asset management company based in
|
||
Shanghai, China, focusing on equity investments in emerging
|
||
industries and healthcare sectors, with exposure to the Hong
|
||
Kong and mainland China capital markets.
|
||
Wang Qiang ( ˮ੶) is the ultimate beneficial owner holding
|
||
30% or more interests in two Shanghai Pinpoint Ultimate
|
||
Clients. No ultimate beneficial owner holds 30% or more
|
||
interests in the other Shanghai Pinpoint Ultimate Client.
|
||
To the best knowledge of CSICM after making all reasonable
|
||
enquiries, each of the Shanghai Pinpoint Ultimate Clients and
|
||
their respective ultimate beneficial owners is an independent
|
||
third party of (i) CSICM, CLSA and the companies which are
|
||
members of the same group of CLSA and (ii) the Company,
|
||
its subsidiaries, the Single Largest Group of Shareholders (as
|
||
defined in the Prospectus) and its substantial shareholders.
|
||
|
||
|
||
--- page 51 ---
|
||
51
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
11. CSICM (in
|
||
connection
|
||
with Shenzhen
|
||
Baoheng OTC
|
||
Swaps)
|
||
CSICM, CITICS and
|
||
CLSA are members
|
||
of the same group of
|
||
companies.
|
||
Non-discretionary
|
||
on behalf of
|
||
third parties
|
||
200 CSICM and CITICS will enter into a series of cross border
|
||
OTC swap transactions ( “Shenzhen Baoheng OTC Swaps ”)
|
||
with Shenzhen Baoheng Investment Co., Ltd. ( ଉέᘒ㛬ҳ༟
|
||
ʮ̡ ) (“Shenzhen Baoheng ”), pursuant to which CSICM
|
||
will hold the Offer Shares to be subscribed for and on behalf
|
||
of Shenzhen Baoheng on a non-discretionary basis to hedge the
|
||
Shenzhen Baoheng OTC Swaps while the economic risks and
|
||
returns of the underlying Offer Shares are passed Shenzhen
|
||
Baoheng, subject to customary fees and commissions. CSICM
|
||
will not take part in any economic returns or bear any economic
|
||
losses in relation to the Offer Shares. CSICM undertakes that it
|
||
will not exercise any voting rights attached to the Offer Shares.
|
||
The ultimate beneficial owner of Shenzhen Baoheng is Zhang
|
||
Guofeng ( ੵቜ).
|
||
Shenzhen Baoheng is an investment company focusing on
|
||
equity and alternative investments, with particular interest
|
||
in emerging markets and the healthcare sector, including
|
||
opportunities in the Hong Kong capital market.
|
||
It is submitted that, pursuant to the confirmation of Shenzhen
|
||
Baoheng, each of Shenzhen Baoheng and its ultimate
|
||
beneficial owner is independent from each of the Company, its
|
||
subsidiaries and substantial shareholders.
|
||
0.0002% 0.0001%
|
||
|
||
|
||
--- page 52 ---
|
||
52
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
To the best knowledge of CSICM after making all reasonable
|
||
enquiries, each of Shenzhen Baoheng and its ultimate beneficial
|
||
owner is an independent third party of (i) CSICM, CLSA and
|
||
the companies which are members of the same group of CLSA
|
||
and (ii) the Company, its subsidiaries, the Single Largest
|
||
Group of Shareholders (as defined in the Prospectus) and its
|
||
substantial shareholders.
|
||
12. CITIC Asset
|
||
Management
|
||
CITIC Asset
|
||
Management is a
|
||
member of the same
|
||
group of CLSA
|
||
Discretionary 8,800 CITIC Asset Management will hold the Offer Shares in its
|
||
capacity as the discretionary fund manager managing the
|
||
funds on behalf of their underlying clients, each of which is an
|
||
independent third party.
|
||
No ultimate beneficial owner holds 30% or more interest
|
||
therein.
|
||
0.010% 0.002%
|
||
13. China AMC HK China AMC HK is a
|
||
member of the same
|
||
group of CLSA
|
||
Discretionary 19,000 China AMC HK will hold the Offer Shares in its capacity
|
||
as the discretionary fund manager managing on behalf of its
|
||
underlying clients, each of which is an independent third party.
|
||
The information of the funds are set out below:
|
||
0.021% 0.005%
|
||
|
||
|
||
--- page 53 ---
|
||
53
|
||
No.
|
||
Name of
|
||
connected
|
||
client
|
||
Name of
|
||
connected
|
||
distributor
|
||
Relationship with
|
||
the connected
|
||
distributor
|
||
Basis of holding
|
||
securities
|
||
Number of
|
||
Offer Shares
|
||
subscribed
|
||
Ultimate beneficial owner of the Offer
|
||
Shares allocated to the connected client
|
||
Percentage of the
|
||
Offer Shares
|
||
subscribed (assuming
|
||
the Over-allotment
|
||
Option is not
|
||
exercised and taking
|
||
into account full
|
||
exercise of the offer
|
||
size adjustment option)
|
||
Percentage of the
|
||
issued Shares of the
|
||
Company immediately
|
||
upon completion of
|
||
the Global Offering
|
||
(assuming the Over-
|
||
allotment Option is
|
||
not exercised and
|
||
taking into account full
|
||
exercise of the offer size
|
||
adjustment option)
|
||
1. CHINAAMC CHINA FOCUS FUND -
|
||
254900G5YFZ5OTQS0G14: the ultimate beneficial owner
|
||
holding 30% or more is Manulife (International) Limited -
|
||
549300E1S6OED3RZ2B22 with 78.74% interest;
|
||
2. CHINAAMC FUND – CHINAAMC CHINA
|
||
OPPORTUNITIES FUND - 213800LFHQWQ1J2I7875:
|
||
No ultimate beneficial owner holds 30% or more interest
|
||
therein; and
|
||
3. CHINAAMC CHINA GROWTH FUND (SICAV) -
|
||
213800OL1K8299ZA3F59: the ultimate beneficial owner
|
||
holding 30% or more is Yuanta Securities (HK) Company
|
||
LTD - 3003006CJLCA4YV6DX47 with 68.53% interest.
|
||
|
||
|
||
--- page 54 ---
|
||
54
|
||
Note:
|
||
1. Please see below for the background on the non-SFC authorized collective investment schemes:
|
||
Fund name
|
||
Types and values
|
||
of assets under
|
||
management
|
||
Whether
|
||
the scheme
|
||
is publicly
|
||
marketed
|
||
Scheme
|
||
establishment
|
||
date
|
||
Identities of the general
|
||
partners and the 20 largest
|
||
limited partners of the
|
||
scheme where applicable
|
||
Identity of the scheme
|
||
administrator
|
||
Relationships among the scheme, the
|
||
ultimate beneficial owner(s) of the
|
||
limited partner(s), the largest group
|
||
of the shareholders of the Company,
|
||
and the Company
|
||
Value Partners China
|
||
A-Share Innovation
|
||
Fund SP
|
||
Private fund,
|
||
USD22 million
|
||
as of Dec 2024
|
||
No 19/11/2018 Not applicable, as it ’s a
|
||
private fund company
|
||
HSBC Trustee (Cayman)
|
||
Limited
|
||
The scheme and ultimate beneficial
|
||
owners are independent third parties
|
||
of GF Securities (Hong Kong)
|
||
Brokerage, the Company and the
|
||
Single Largest Group of Shareholders
|
||
of the Company
|
||
Value Partners
|
||
Intelligent Funds –
|
||
JA-VP China New
|
||
Century Fund
|
||
Private fund,
|
||
USD4.8 million
|
||
as of Dec 2024
|
||
No 7/3/2002 No applicable, as it ’s a private
|
||
fund company
|
||
HSBC Trustee (Cayman)
|
||
Limited
|
||
The scheme and ultimate beneficial
|
||
owners are independent third parties
|
||
of GF Securities (Hong Kong)
|
||
Brokerage, the Company and the
|
||
Single Largest Group of Shareholders
|
||
of the Company
|
||
|
||
|
||
--- page 55 ---
|
||
55
|
||
DISCLAIMERS
|
||
Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the
|
||
“Stock Exchange ”) and Hong Kong Securities Clearing Company Limited ( “HKSCC ”) take no
|
||
responsibility for the contents of this announcement, make no representation as to its accuracy
|
||
or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising
|
||
from or in reliance upon the whole or any part of the contents of this announcement.
|
||
This announcement is not for release, publication, distribution, directly or indirectly, in or into
|
||
the United States (including its territories and possessions, any state of the United States and
|
||
the District of Columbia). This announcement does not constitute or form a part of any offer or
|
||
solicitation to purchase or subscribe for securities in the United States. The securities mentioned
|
||
herein have not been, and will not be, registered under the United States Securities Act of 1933,
|
||
as amended (the “U.S. Securities Act ”). The securities may not be offered or sold in the United
|
||
States except pursuant to an exemption from the registration requirements of the U.S. Securities
|
||
Act and in compliance with any applicable state securities laws, or outside the United States
|
||
unless in compliance with Regulation S under the U.S. Securities Act. There will be no public
|
||
offer of securities in the United States.
|
||
The Offer Shares are being offered and sold (1) solely to qualified institutional buyers as defined
|
||
in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under
|
||
the U.S. Securities Act and (2) outside the United States in offshore transactions in reliance on
|
||
Regulation S under the U.S. Securities Act.
|
||
This announcement is for information purposes only and does not constitute an invitation or
|
||
offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus.
|
||
Potential investors should read the Prospectus dated September 11, 2025 issued by GenFleet
|
||
Therapeutics (Shanghai) Inc. for detailed information about the Global Offering described below
|
||
before deciding whether or not to invest in the H Shares thereby being offered.
|
||
* Potential investors of the Offer Shares should note that the Sole Sponsor and the Sole
|
||
Sponsor-Overall Coordinator (for itself and on behalf of the Hong Kong Underwriters) shall
|
||
be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with
|
||
immediate effect upon the occurrence of any of the events set out in the paragraph headed
|
||
“Underwriting – Underwriting Arrangements and Expenses –– Hong Kong Public Offering ––
|
||
Grounds for Termination ” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on
|
||
the Listing Date (which is currently expected to be on September 19, 2025).
|
||
PUBLIC FLOAT AND FREE FLOAT
|
||
Immediately after the completion of the Global Offering, 257,082,300 H Shares, representing
|
||
approximately 72.02% of the issued share capital of our Company (before any exercise of the
|
||
Over-allotment Option) will count towards the public float. Therefore, the number of H shares held
|
||
in public hands is higher than the prescribed percentage of H Shares required to be held in public
|
||
hands of 20.61% under Rule 19A.13A(1) of the Listing Rules, satisfying the minimum percentage
|
||
requirement in compliance with Rule 19A.13A(1) of the Listing Rules. Based on the Offer Price of
|
||
HK$20.39 per H Share, the Company satisfies the free float requirement under Rule 19A.13C(1)(b)
|
||
of the Listing Rules.
|
||
|
||
|
||
--- page 56 ---
|
||
56
|
||
The Directors confirm that, immediately following completion of the Global Offering: (i) the
|
||
Shares will be held by at least 300 Shareholders at the time of Listing, in compliance with Rule
|
||
8.08(2) of the Listing Rules; (ii) the three largest public Shareholders will not hold more than
|
||
50% of the H Shares held in public hands at the time of Listing, in compliance with Rules 8.08(3)
|
||
and 8.24 of the Listing Rules; (iii) no placee will, individually, be placed more than 10% of the
|
||
enlarged issued share capital of the Company immediately after the Global Offering; and (iv) there
|
||
will not be any new substantial Shareholder (as defined in the Listing Rules) immediately after the
|
||
Global Offering.
|
||
COMMENCEMENT OF DEALINGS
|
||
The H Share certificates will only become valid evidence of title at 8:00 a.m. (Hong Kong time)
|
||
on Friday, September 19, 2025, provided that (i) the Global Offering has become unconditional
|
||
in all respects, and (ii) the right of termination described in the section headed “Underwriting {
|
||
Underwriting Arrangements and Expenses { Hong Kong Underwriting Agreement { Grounds for
|
||
termination ” in the Prospectus has not been exercised. Investors who trade H Shares prior to the
|
||
receipt of H Share certificates or the H Share certificates becoming valid evidence of title do so
|
||
entirely at their own risk.
|
||
Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. (Hong Kong time)
|
||
on Friday, September 19, 2025, it is expected that dealings in the H Shares on the Stock Exchange
|
||
will commence at 9:00 a.m. on Friday, September 19, 2025. The H Shares will be traded in board
|
||
lots of 200 H Shares each and the stock code of the H Shares will be 2595.
|
||
By order of the Board
|
||
GenFleet Therapeutics (Shanghai) Inc.
|
||
Dr. Qiang LU
|
||
Chairman and Executive Director
|
||
Hong Kong, September 18, 2025
|
||
Directors and proposed directors of the Company named in the application to which this
|
||
announcement relates are Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive
|
||
directors, Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors, and Ms. Christine
|
||
Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as proposed independent non-executive
|
||
directors.
|